Ownership Submission
FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Berkley Capital Investors, L.P.
2. Date of Event Requiring Statement (Month/Day/Year)
07/30/2014
3. Issuer Name and Ticker or Trading Symbol
HEALTHEQUITY INC [HQY]
(Last)
(First)
(Middle)
475 STEAMBOAT ROAD
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

GREENWICH, CT 06830
6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Series C Preferred Stock   (1)   (1) Common Stock 7,157,346 $ (1) D  
Series D-1 Preferred Stock   (1)   (1) Common Stock 5,152,986 $ (1) D  
Series D-2 Preferred Stock   (1)   (1) Common Stock 909,090 $ (1) D  
Series D-3 Preferred Stock   (1)   (1) Common Stock 825,868 $ (1) D  
Stock Option (right to buy)   (2) 03/26/2019 Common Stock 30,000 $ 1.1 D  
Stock Option (right to buy)   (2) 01/17/2017 Common Stock 30,000 $ 1.1 D  
Stock Option (right to buy)   (2) 01/17/2018 Common Stock 30,000 $ 1.1 D  
Stock Option (right to buy)   (2) 04/15/2020 Common Stock 30,000 $ 1.1 D  
Stock Option (right to buy)   (2) 04/29/2021 Common Stock 30,000 $ 1.8 D  
Stock Option (right to buy)   (2) 04/26/2022 Common Stock 30,000 $ 2.25 D  
Stock Option (right to buy)   (2) 05/09/2023 Common Stock 30,000 $ 2.5 D  
Warrant (right to buy)   (3) 05/21/2017 Common Stock 813,713 $ 0.01 D  
Warrant (right to buy)   (3) 02/07/2018 Common Stock 143,147 $ 1.68 D  
Warrant (right to buy)   (4) 08/11/2016 Common Stock 182,000 $ 0.01 D  
Series C Preferred Stock   (1)   (1) Common Stock 7,157,346 $ (1) I See footnote (5)
Series D-1 Preferred Stock   (1)   (1) Common Stock 5,152,986 $ (1) I See footnote (5)
Series D-2 Preferred Stock   (1)   (1) Common Stock 909,090 $ (1) I See footnote (5)
Series D-3 Preferred Stock   (1)   (1) Common Stock 825,868 $ (1) I See footnote (5)
Stock Option (right to buy)   (2) 03/26/2019 Common Stock 30,000 $ 1.1 I See footnote (5)
Stock Option (right to buy)   (2) 01/07/2017 Common Stock 30,000 $ 1.1 I See footnote (5)
Stock Option (right to buy)   (2) 01/07/2018 Common Stock 30,000 $ 1.1 I See footnote (5)
Stock Option (right to buy)   (2) 04/15/2020 Common Stock 30,000 $ 1.1 I See footnote (5)
Stock Option (right to buy)   (2) 04/29/2021 Common Stock 30,000 $ 1.8 I See footnote (5)
Stock Option (right to buy)   (2) 04/26/2022 Common Stock 30,000 $ 2.25 I See footnote (5)
Stock Option (right to buy)   (2) 05/09/2023 Common Stock 30,000 $ 2.5 I See footnote (5)
Warrant (right to buy)   (3) 05/21/2017 Common Stock 813,713 $ 0.01 I See footnote (5)
Warrant (right to buy)   (3) 02/07/2018 Common Stock 143,147 $ 1.68 I See footnote (5)
Warrant (right to buy)   (4) 08/11/2016 Common Stock 182,000 $ 0.01 I See footnote (5)

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Berkley Capital Investors, L.P.
475 STEAMBOAT ROAD
GREENWICH, CT 06830
    X    
Berkley Capital, LLC
475 STEAMBOAT ROAD
GREENWICH, CT 06830
    X    

Signatures

BERKLEY CAPITAL INVESTORS, L.P., By: BERKLEY CAPITAL, LLC, its general partner, By: /s/ Frank Medici, its President 07/28/2014
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The reported securities automatically will convert into shares of common stock on the business day immediately prior to the closing date of the initial public offering of HealthEquity, Inc.
(2) The option is immediately exercisable.
(3) The warrant is immediately exercisable.
(4) The warrant is immediately exercisable and will terminate upon the earlier of (i) August 11, 2016 and (ii) the closing of the initial public offering of HealthEquity, Inc.
(5) See Exhibit 99.1 for the text of footnote (5).
 
Remarks:
Exhibit List:

Exhibit 99.1 - Explanation of Responses
Exhibit 99.2 - Joint Filers' Names and Addresses
Exhibit 99.3 - Joint Filers' Signatures

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.